

1 *Clinical effects and adverse events of desflurane in adult patients undergoing*  
2 *supratentorial craniotomy: A systematic review*

3

4 *Georgios Gkantinas, MD, Department of Anesthesiology, General Hospital of Nikaia,*  
5 *Piraeus, Greece*

6 *Eleni I. Tataki, MD, Department of Anesthesiology, General Hospital of Nikaia, Piraeus,*  
7 *Greece*

8 *Panagis M. Lykoudis, MD PhD, Division of Surgery & Interventional Science, University*  
9 *College London (UCL), London, UK*

10 *Eleftheria Lelekaki, MD MSc, Intensive Care Unit, Naval Hospital of Athens, Greece*

11 *Pinelopi Kouki, MD PhD MSc DESA, Department of Anesthesiology, General Hospital*  
12 *of Nikaia, Piraeus, Greece*

13

14

15 *Correspondence to Georgios Gkantinas, Department of Anesthesiology, General*  
16 *Hospital of Nikaia, Piraeus.*

17 *Email: gadinasgio@gmail.com*

18 *Address: Dim. Mantouvalou 3, Nikaia, 184 54, Greece.*

19 *Sources of support that require acknowledgment: none*

20 *Conflicts of interest: none*

21

22 *Short title : Desflurane in intracranial surgery: systematic review*

23

24 **Abstract**

25 Desflurane is an inhalational anesthetic agent with an appealing recovery profile. Its use  
26 during craniotomies however, has been limited. The present systematic review  
27 investigates the clinical effects and adverse events of desflurane use during supratentorial  
28 craniotomies for brain tumor resection in adult patients, in comparison to other  
29 inhalational and/or intravenous agents. Literature search was conducted across the  
30 following databases MEDLINE, Library of Congress and LISTA (EBSCO) from January  
31 2001 to January 2021. Twelve studies from 2003 to 2020 were included in this systematic  
32 review. Desflurane was compared to either isoflurane, sevoflurane or propofol for  
33 anesthesia maintenance. Regarding the primary outcomes studied, brain relaxation scores  
34 showed no statistically significant difference between desflurane and the other anesthetic  
35 agents. Recovery timepoints, such as time to recovery, time to eye opening, time to  
36 extubation, time to follow commands and time to reach a “Modified Aldrete Score” equal  
37 or above 9 were significantly shorter in the desflurane arm in the majority of studies.  
38 Systemic hemodynamic variables, mean arterial pressure and heart rate, as well as  
39 cerebral hemodynamics, intracranial pressure and cerebrospinal fluid pressure were  
40 comparable between anesthetic agents and desflurane, in each study. Results of this  
41 systematic review demonstrate that desflurane is a hypnotic agent with few adverse events  
42 for anesthesia maintenance in adult patients undergoing supratentorial brain tumor  
43 surgery. Large, prospective, comprehensive studies, utilizing standardized parameter  
44 evaluation could provide higher level of evidence.

45

46

47 *Key words: anesthesia, craniotomy, desflurane, inhalational, supratentorial, volatile*

48

49 **Introduction**

50

51 Early patient recovery after brain surgery is considered one of the main goals of the  
52 anesthesia plan. Desflurane due to its unique pharmacokinetic and pharmacodynamic  
53 profile, can contribute to prompt extubation, even after prolonged duration of anesthesia.<sup>1</sup>  
54 This characteristic allows early neurologic evaluation and early recognition of disastrous  
55 postoperative complications, such as seizures, increased intracranial pressure or  
56 hemorrhage can be identified and treated accordingly.

57 Desflurane is a fluorinated methyl ethyl ether. It has low blood/gas, fat/blood and  
58 brain/blood partition coefficients, which favor its rapid elimination and early recovery of  
59 consciousness.<sup>2</sup> Desflurane is advantageous due to limited metabolism and adipose tissue  
60 storage and is considered to be a safe anesthetic choice in several surgical populations.<sup>1</sup>  
61 Concerning cerebral physiology, desflurane can decrease cerebral metabolic rate and  
62 oxygen consumption.<sup>3</sup> On the other hand, regarding systemic hemodynamics, desflurane  
63 can decrease mean arterial pressure and consequently cerebral perfusion pressure. There  
64 have been doubts regarding its superiority in brain surgery, due to its physiologic effect  
65 to promote cerebral vasodilatation and increase cerebral blood flow (CBF) and cerebral  
66 blood volume both in animal and human studies.<sup>3</sup> In theory, this could promote an  
67 increase in intracranial pressure (ICP), which could have detrimental effects on patients  
68 with intracranial pathology. Recent studies though, have demonstrated that desflurane at  
69 1.0 MAC does not increase intracranial pressure in normocapnic patients.<sup>4</sup> Over the past  
70 years, there has been an increasing body of evidence showing that desflurane can be an

71 acceptable alternative to other volatile or intravenous hypnotic agents for brain surgery.  
72 However, to the best of the authors' knowledge, there is no systematic review or meta-  
73 analysis on this topic. Although this is not a meta-analysis, we aim to present a systematic  
74 review after examining current evidence regarding adverse and clinical effects of  
75 desflurane, as the main anesthetic agent for supratentorial brain tumor resection in adult  
76 patients.

77

## 78 **Methods**

### 79 Search strategy

80 A systematic search was conducted in May 2021 by two independent researchers across  
81 three databases, MEDLINE, Library of Congress and LISTA (EBSCO). Search strategy  
82 included the following terms, organized in two blocks. Block A included the terms:  
83 desflurane OR volatile an(a)esthetics OR volatile an(a)esthesia OR inhaled an(a)esthetics  
84 OR inhaled an(a)esthesia OR inhalation an(a)esthetics OR inhalational an(a)esthesia.  
85 Block B included the terms: neurosurgery OR neurosurgical OR brain surgery OR  
86 craniotomy OR intracranial OR meningioma OR glioblastoma OR supratentorial OR  
87 infratentorial. Search terms from the two blocks were combined in pairs to employ all  
88 different combinations. Literature search was restricted to articles published during the  
89 last twenty years. Reference lists of the examined articles were also searched for relevant  
90 results.

### 91 Study selection

92 Studies were selected according to the PICOS approach. After initial search, two  
93 reviewers independently screened the articles by title and abstract to identify pertinent  
94 studies. Articles not excluded through this process, were read thoroughly in order to

95 determine their suitability. Exclusion criteria included non-human studies, non-adult  
96 population, case series, non-comparative studies, review articles and articles not in  
97 English. Criteria for inclusion were articles in English, prospective and retrospective  
98 comparative studies, both randomized and non-randomized, having desflurane and other  
99 anesthetic agents as comparison arms, studies on human adult population and studies on  
100 craniotomies for tumor resection. Articles that were published during the last twenty  
101 years, since 2001, were included in this review. In case of disagreement, a third  
102 independent reviewer was consulted for resolution. (See supplemental table: The PICOS  
103 model)

#### 104 Data collection

105 Data from the included studies were extracted independently by two reviewers and cross  
106 checked by a third one. Extracted data included first author's name, year of publication,  
107 type of operation, number of patients included, demographic characteristics, anesthetic  
108 agents used, results about primary and secondary outcomes. Primary outcomes included  
109 brain relaxation score, time to emergence (minutes), time to recovery (minutes), time to  
110 extubation (minutes), time to follow commands (minutes), time to reach Modified Aldrete  
111 Score (MAS) equal or greater than 9, perioperative systemic hemodynamic parameters,  
112 mean arterial pressure (MAP) in mmHg, heart rate (HR) in beats per minute, cerebral  
113 hemodynamic parameters, intracranial pressure (ICP) in mmHg, cerebral perfusion  
114 pressure (CPP) in mmHg, lumbar cerebrospinal fluid pressure (LCSFP) in mmHg.  
115 Secondary outcomes included, perioperative gas exchange patterns (PaO<sub>2</sub> and PaCO<sub>2</sub> in  
116 mmHg), quality of recovery using the "Short Orientation Memory Concentration Test"  
117 (SOMCT) or "Rancho Los Amigos scale" (RLAS), perioperative blood glucose trends,  
118 emergence agitation (%), postoperative nausea and/or vomiting (PONV) (%),

119 postoperative shivering (%), patient satisfaction (%) and survival parameters. Satisfaction  
120 about the quality of anesthesia was graded by patients on a three point scale,  
121 “dissatisfied”, “neither dissatisfied nor satisfied” and “satisfied”, twenty four hours after  
122 surgery. Regarding systemic and cerebral hemodynamics, gas exchange patterns and  
123 perioperative glucose trends, as timing of measurement differed widely across studies,  
124 only results about the presence or absence of statistical difference were extracted by the  
125 authors. Numerical results about these outcomes were not extracted and compared across  
126 studies, unless it was clear that metrics were obtained the exact same time point during  
127 the perioperative period. All information collected was tabulated to allow analysis.

#### 128 Risk of bias assessment

129 Included studies were assessed for risk of bias independently by two reviewers.  
130 Resolution by a third reviewer was sought in case of disagreement. The Cochrane tool for  
131 assessing risk of bias in randomized trials (ROB 2) was used.<sup>5</sup> Methodological quality  
132 for each of these studies was assessed in five different domains and a final overall risk of  
133 bias judgement was reached. Based on the overall risk of bias judgement, studies were  
134 graded as “low risk of bias”, “some concerns” or “high risk of bias”. For non-randomized  
135 studies, methodological quality was assessed according to the “Methodological Index For  
136 Non-randomized Studies” (MINORS).<sup>6</sup>

#### 137 Protocol

138 This systematic review was registered in the International Prospective Register of  
139 Systematic Reviews (PROSPERO) as CRD4202123824 on March 31, 2021. The study  
140 was conducted and reported according to Preferred Reporting Items for Systematic  
141 Reviews and Meta-Analyses (PRISMA) guidelines.<sup>7</sup>

142 [www.crd.york.ac.uk/prospero/display\\_record.php?RecordID=238243](http://www.crd.york.ac.uk/prospero/display_record.php?RecordID=238243)

143

144 **Results**

## 145 Study selection

146 The initial search strategy yielded forty-three studies. After deduplication and suitability  
147 screening, eleven studies were retained for analysis. Screening of reference lists yielded  
148 one additional result. Study selection is shown in figure 1. The present study finally  
149 included twelve articles published from 2003 to 2020. All included studies were  
150 prospective randomized with the exception of one retrospective study. The type of  
151 operation was supratentorial craniotomy for intracranial lesions consistently across all  
152 included studies. Although, the search strategy also included the term “infratentorial”,  
153 no suitable study on infratentorial surgery was found. Therefore, the present systemic  
154 review focuses only on supratentorial craniotomy. Anesthetic agents used for comparison  
155 included sevoflurane and isoflurane, in six studies each, and propofol in two. (Table 1)

156

## 157 Demographics

158 The size of included studies varied considerably, Cata et al.<sup>8</sup> being the largest (261 for  
159 the desflurane arm vs 117 patients for the isoflurane arm) and Boisson et al.<sup>9</sup> the smallest  
160 (16 for desflurane vs 17 for isoflurane). Patients' demographics (median age in years, %  
161 female) were also considerably different across studies. Dube et al.<sup>10</sup> reported the  
162 youngest median age (34,9 for the desflurane group vs 39,5 years for sevoflurane),  
163 whereas Magni et al.<sup>11</sup> reported the oldest (60,4 for desflurane vs 62,4years for  
164 sevoflurane). Kaye et al.<sup>12</sup> included the highest percentage of females (66.6 in the  
165 desflurane group vs 61.1 in the isoflurane group) in contrast to Bastola et al.<sup>13</sup> who had  
166 the lowest (32.0 for desflurane vs 28.0 for sevoflurane vs 28.0 for propofol). (Table 1)

167

168 Primary outcomes

169 Brain relaxation scores was reported in five studies.<sup>10,13,14,15,16</sup> For the evaluation of brain  
170 relaxation, a score ranging from 1, representing completely relaxed brain, to 4,  
171 representing tight brain, was used in all studies. No study showed statistically significant  
172 difference between desflurane and other anesthetic agents. Time to eye opening, defined  
173 as the time between the anesthetic agent cessation and patient's eye opening, was reported  
174 in eight articles.<sup>9,10,11,12,14,15,16,17</sup> In five of them , anesthesia with desflurane resulted in  
175 significantly shorter times overall,<sup>9,14,15,16,17</sup> whereas the rest reported no statistically  
176 significant differences.<sup>10,11,12</sup> A similar trend was observed with time to extubation, which  
177 was reported in eight articles.<sup>9,10,11,13,14,15,16,17</sup> Statistically shorter time to extubation in  
178 the desflurane group was seen in five out of the eight studies.<sup>9,11,14,15,17</sup> Results concerning  
179 time to recovery were reported in seven studies,<sup>9,10,11,14,15,16,17</sup> although the definitions  
180 implemented for recovery were inconsistent across them. For this review, "time to  
181 recovery" was defined as the time from anesthetic agent's discontinuation to patient's  
182 orientation after verbal stimuli. Statistically significant results reporting shorter times  
183 with desflurane were seen in five studies,<sup>9,11,15,16,17</sup> whereas the other two studies reported  
184 no statistical difference.<sup>10,14</sup> Similarly with time to recovery, a clear and common  
185 definition of the time to follow commands was not available across the included studies.  
186 Three studies reported results about time to follow commands<sup>12,13,16</sup> and two reported  
187 about time to hand gripping.<sup>9,17</sup> In the present review, time to hand gripping was  
188 considered the same as time to follow commands. In four out of five studies, anesthesia  
189 with desflurane resulted in shorter time with statistically significant difference .<sup>9,13,16,17</sup>  
190 Time to reach a score equal to or greater than 9 according to MAS was reported in three

191 studies,<sup>14,17,18</sup> all reporting significantly shorter times in the desflurane arm. One study  
192 used a MAS equal to or above 8 in their methodology,<sup>15</sup> also reporting significantly  
193 shorter time with desflurane.

194 Regarding systemic hemodynamics, results about MAP and HR were reported in  
195 seven<sup>4,9,10,12,13,14,15</sup> and eight studies,<sup>4,9,10,12,13,14,15,16</sup> respectively. Mean arterial pressure  
196 values were reported to be comparable in the majority of the studies. However, one  
197 study<sup>15</sup> showed significantly higher MAP values with desflurane at various timepoints  
198 (Table 2). Heart rate values between desflurane and other hypnotic agents were, also,  
199 comparable in all studies except one, which reported statistically higher values in the  
200 sevoflurane arm.<sup>13</sup> Intracranial pressure, CPP and LCSFP were measured and reported in  
201 four,<sup>4,10,12,16</sup> two<sup>4,12</sup> and one<sup>12</sup> studies, respectively. No study reported statistically  
202 significant difference. Results about primary outcomes are shown in Table 2.

203

204

205 Secondary outcomes

206 Despite the fact that results about these parameters were scarcely reported, authors  
207 considered them important for the scope of this review. Evaluation of recovery after  
208 anaesthesia using SOMCT was completed in three out of the twelve studies.<sup>14,10,11</sup> In two  
209 studies,<sup>11,14</sup> the desflurane group had significantly higher SOMCT scores, indicating  
210 improved recovery, but only at earlier time points (Table 3). No difference was shown at  
211 later timepoints. RLAS results were reported in one study and results showed a similar  
212 trend as with SOMCT.<sup>14</sup> Gas exchange pattern trends, namely, PaO<sub>2</sub> and PaCO<sub>2</sub>, were  
213 studied in three<sup>11,14,16</sup> and four articles,<sup>4,11,14,16</sup> respectively. The majority of the articles  
214 did not show a statistically significant difference. Only one study demonstrated

215 statistically lower PaCO<sub>2</sub> values in the desflurane arm at two timepoints, 15 and 30 min  
216 post extubation.<sup>14</sup> Perioperative blood glucose trends, among anesthesia with desflurane,  
217 sevoflurane and propofol were reported in, only, one study that showed statistically  
218 significant results in favor of propofol for achieving steadier blood glucose levels.<sup>18</sup>  
219 Emergence agitation was reported in two studies.<sup>10,13</sup> Neither of the results was  
220 statistically significant. The incidence of postoperative nausea and/or vomiting (PONV)  
221 and postoperative shivering was reported in seven<sup>9,10,11,13,14,17,18</sup> and four studies,<sup>9,10,11,14</sup>  
222 respectively. None of these studies showed a statistically significant difference. Patient  
223 satisfaction after anesthesia was reported in one study.<sup>18</sup> There was no difference in rates  
224 of patient satisfaction among those who received desflurane, sevoflurane, or propofol.  
225 Only one retrospective study measured long-term survival after craniotomies for  
226 glioblastoma multiforme.<sup>8</sup> Desflurane and isoflurane were found to have comparable  
227 progression free survival (PFS) and overall survival (OS) rates. Overall survival rates at  
228 three years were found to be 0.27 in the desflurane group and 0.35 in isoflurane arm,  
229 whereas, at five years the desflurane arm had a survival rate of 0.15 compared to 0.16  
230 with isoflurane. Secondary outcomes results are shown in Table 3.

231

### 232 Risk of Bias (Rob2)

233 No disagreements between the reviewers were encountered while assessing for risk of  
234 bias. Two studies were assessed as having an overall high risk of bias.<sup>9,10</sup> The first was  
235 due to having some concerns regarding “deviations from intended interventions” and due  
236 to having high risk in “measurement of the outcome”.<sup>9</sup> The second was due to raising  
237 “some concerns” in three domains “randomization process”, “deviations from intended  
238 interventions” and “measurement of the outcome”.<sup>10</sup> Three studies had a moderate overall

239 risk of bias.<sup>11,13,17</sup> The studies of Gökçek et al.<sup>17</sup> and Bastola et al.<sup>13</sup> raised “some  
240 concerns” in two categories: “deviations from intended interventions” as well as  
241 “measurement of the outcome”. Study of Magni et al.<sup>11</sup> raised “some concerns” in  
242 “randomization process” and “deviations from intended interventions”. Six studies were  
243 appraised as having a low risk of bias in each domain and overall.<sup>4,12,14,15,16,18</sup> A summary  
244 of Rob2 assessment is depicted in Figure 2.

245 **MINORS criteria**

246 One retrospective non-randomized study was assessed using the MINORS criteria.<sup>8</sup> For  
247 comparison purposes, scores were calculated for all the studies. The scores ranged  
248 between 10<sup>9,13</sup> and 14<sup>14,17,18</sup>. The one non-randomized retrospective study was assigned  
249 a score of 13.<sup>8</sup> Overall, the main reasons for missing points were, “follow-up duration”  
250 declaration and “loss to follow-up” declaration. Among all studies only Cata et al.<sup>8</sup>  
251 presented accurate data on both categories. Failure of a clear statement regarding  
252 “inclusion of consecutive patients” was the second most common reason for missed  
253 points. Four studies received the maximum of 2 points,<sup>12,14,17,18</sup> six studies received the  
254 intermediate of 1 point,<sup>8,10,11,13,15,16</sup> and two studies received no points.<sup>4,9</sup> Outcome  
255 evaluation bias was the third most common reason for missing points. Six studies received  
256 a maximum score,<sup>11,14,15,16,17,18</sup> one study received no points,<sup>8</sup> and five received 1  
257 point.<sup>4,9,10,12,13</sup> Evaluation according to the MINORS criteria is summarized in  
258 supplemental digital content table: MINORs scores.

259

## 260 **Discussion**

261 With reference to primary outcomes studied in this review, desflurane proves to be an  
262 anesthetic with few adverse events in craniotomies for brain tumor resection in adult

263 patients. Systemic and cerebral hemodynamic variables, as well as brain relaxation scores  
264 were comparable between desflurane and other anesthetic agents with no statistically  
265 significant difference. Moreover, anesthesia maintenance with desflurane consistently  
266 resulted in shorter recovery times. It should be noted, though, that all patients included in  
267 this review showed normal ICP values preoperatively. Regarding secondary outcomes,  
268 quality of recovery after anesthesia using SOMCT and RLAS test appeared to be better  
269 with desflurane, but statistically significant only at the earlier postoperative period. In a  
270 similar trend, PaCO<sub>2</sub> did not differ in most of the studies, except for one study<sup>14</sup> in obese  
271 patients, which reported statistically lower PaCO<sub>2</sub> values in the desflurane arm, but only  
272 at earlier time points of the first postoperative hour. Clinically, this translates to lower  
273 postoperative sedation in the desflurane group. Emergence agitation, POVN,  
274 postoperative shivering and patient satisfaction were all statistically comparable among  
275 the anesthetic agents. Finally, statistically significant results against desflurane were  
276 reported only by Halder et al. regarding perioperative blood glucose values.<sup>18</sup> In this  
277 study, the propofol group achieved more stable plasma glucose values perioperatively  
278 compared to desflurane and sevoflurane.

279 To the best of the authors' knowledge, this is the first systematic review on this topic. A  
280 recent narrative review,<sup>19</sup> showed findings similar to ours and supports the role of third  
281 generation fluorinated hypnotic agents in adult patients undergoing craniotomies.  
282 Regarding recovery parameters in other surgical populations, a number of systematic  
283 reviews and meta-analyses are available. In the case of elderly patients, Chen et al.  
284 concluded that desflurane arm had consistently statistically significant shorter recovery  
285 times compared to sevoflurane.<sup>20</sup> Also, in a meta-analysis by Singh et al. comparing  
286 recovery profiles in bariatric surgery similar results are reported, in favor of desflurane.<sup>21</sup>

287 Regarding ambulatory surgery this time, a systematic review by Gupta et al. and a meta-  
288 analysis by Chen et al. concluded with agreeing results to the above.<sup>22,23</sup> It appears that  
289 desflurane's pharmacological properties make it a very appealing anesthetic agent, for a  
290 broad range of surgical populations, from shorter ambulatory surgery to longer lasting  
291 craniotomies, where rapid recovery is necessary for a complete and precise neurological  
292 assessment. A study by Ghoneim et al. not included in this review, due to reference to  
293 pediatric population, reported no difference in brain swelling with desflurane, isoflurane  
294 and sevoflurane and showed significantly faster recovery times in the desflurane group.<sup>24</sup>

295 All studies were assessed on the basis of their primary outcomes, for which a power  
296 analysis was performed. The most frequent problems encountered were with respect to  
297 "randomization process", "deviations from intended interventions" and "measurement of  
298 outcome". In the study by Magni et al.<sup>11</sup> the groups could not be considered equal due to  
299 a small but statistically significant difference in the MAC-hours, a parameter that directly  
300 influences the primary outcome (time to emergence/extubation). In this case, we have to  
301 consider the possibility that desflurane's rapid recovery is due to shorter exposure to the  
302 agent instead of its pharmacokinetic properties. We suggest that in the future more studies  
303 state the MAC-hours, as it is a more objective way to assess the equality of the groups,  
304 compared to anesthesia or surgery duration. The study by Dube et al.<sup>10</sup> was marked as  
305 raising "some concerns" because although baseline differences among the groups were  
306 not significant, the specific process of randomization was not described. In the category  
307 of deviations from intended interventions, five studies presented a moderate risk of bias,  
308 as they were not double-blinded.<sup>9,10,11,13,17</sup> Gokcek et al.<sup>17</sup> mentioned that the data-  
309 collector was blinded to the agent but the anesthesiologist in charge of interventions was  
310 not, and the concentrations of the volatile anesthetics were not constant during the study.

311 For the remaining studies,<sup>9,10,11,13</sup> the main problem was that the anesthesiologist in  
312 charge of extubation and assessment of recovery time was not blinded to the agent. With  
313 respect to “measurement of the outcome” the main reasons for reporting moderate or high  
314 risk of bias were unmeasured differences between groups concerning total doses of other  
315 anesthetics (e.g. opioids), vague criteria concerning important time points (extubation  
316 criteria, eye opening/ spontaneous ventilation upon stimulation or not), concomitant use  
317 of N<sub>2</sub>O and tapering of volatile agents in a possibly not uniform way among the groups.

318 The main reason for missed points according to MINORs assessment was loss of follow-  
319 up or issues with follow-up duration. None of the studies except for one<sup>18</sup> dealt with long-  
320 term oncological outcomes such as tumor recurrence and survival parameters. These are  
321 matters of particular importance, since the study population concerned oncology patients.  
322 Another reason for low MINORS scores, was failure to include consecutive patients,  
323 although reasons were stated on most occasions. Outcome evaluation bias was judged  
324 based on blinding. Only one study received zero points due to the retrospective nature of  
325 the study.<sup>8</sup> All other studies received a score of 1 (inadequate blinding) or 2 (adequate  
326 blinding- blind evaluation of objective endpoints and double-blinded evaluation of  
327 objective endpoints).

328 The present study was a systematic review of a relatively small number of relevant  
329 articles, and as such, publication bias cannot be excluded. Moreover, although most of  
330 the papers included derived from randomized comparative studies, the authors of the  
331 present review decided not to attempt a numerical aggregation in the form of a meta-  
332 analysis. The main reason was the heterogeneity in the definition of certain time-related  
333 parameters. Also, one of the included studies that received a high score according to the  
334 MINORS criteria, had some issues according to the ROB2 assessment.<sup>17</sup> This leaves two

335 articles with high scores according to both assessments.<sup>14,18</sup> Haldar et al.<sup>18</sup> however, did  
336 not report several parameters, that the authors of the present review considered clinically  
337 pertinent. It is also worth mentioning that possible important outcomes which indicate  
338 patients' functional status ,such as Glasgow Coma Scale, Modified Rankin score  
339 or postoperative stroke are scarce or non-existent across current literature. Short  
340 orientation memory concentration test and Rancho Los Amigos score, which test  
341 neurological functional ability, only appear in three and one article each, respectively.  
342 Overall, this study attempted in the most structured and objective way to sum up relevant  
343 evidence on the topic, however its shortcomings reflect the limitations in current  
344 literature.

345 It becomes evident from the above comments that the most important limitation of current  
346 literature is the heterogeneity in the reporting of certain endpoints. Thus, a consensus  
347 needs to be reached regarding the best way to assess time-related parameters. In addition,  
348 blood glucose levels throughout the procedure, hemodynamic, oncological and patient  
349 satisfaction endpoints are very important and need to be reported consistently in future  
350 studies. An adequate number of further good quality and homogenous randomized studies  
351 are required for a meta-analysis to provide the most reliable answers to the clinical  
352 questions this study has examined.

353

### 354 **Conclusion**

355 Overall, in the present systematic review no study was found where the rate of adverse  
356 events was statistically significantly worse in the desflurane group compared to other  
357 anesthetic agents, in adult patients undergoing supratentorial brain tumor surgery.  
358 Systemic and cerebral hemodynamics as well as brain relaxation scores showed no

359 difference between desflurane and other anesthetic agents, within each study. Concerning  
360 recovery parameters, anesthesia maintenance with desflurane consistently produced  
361 superior results. Large, prospective, comprehensive studies, utilizing standardized  
362 parameter evaluation could provide a higher level of evidence.

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385 **Acknowledgement**

386 1. Assistance with the article :none

387 2. Financial support and sponsorship :none

388 3. Conflicts of interest :none

389 4. Presentation :none

390

391

392

393

394

395

396

397

398

399 **References**

400

401 1) Eger EI II, Bowland T, Ionescu P, et al. Recovery and kinetic characteristics of  
402 desflurane and sevoflurane in volunteers after 8-h exposure, including kinetics of  
403 degradation products. *Anesthesiology*. 1997;87:517–26. doi:10.1097/00000542-  
404 199709000-00010

405 2) Malviya S, Lerman J. The blood/gas solubilities of sevoflurane, isoflurane,  
406 halothane, and serum constituent concentrations in neonates and adults. *The*  
407 *Journal of the American Society of Anesthesiologists*. 1990;72(5):793-6. doi:  
408 10.1097/00000542-199005000-00003

409 3) Miller RD. *Miller's Anesthesia*. Philadelphia, Pa: Churchill Livingstone; 2010  
410 :317.

411 4) Fraga M, Rama-Maceiras P, Rodiño S, et al. The effects of isoflurane and  
412 desflurane on intracranial pressure, cerebral perfusion pressure, and cerebral  
413 arteriovenous oxygen content difference in normocapnic patients with  
414 supratentorial brain tumors. *Anesthesiology*. 2003;98(5):1085-90. doi:  
415 10.1097/00000542-200305000-00010

416 5) Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of  
417 bias in randomized trials. *BMJ* 2019; 366:14898. doi: 10.1136/bmj.14898

418 6) Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized  
419 studies (minors): development and validation of a new instrument. *ANZ journal*  
420 *of surgery* . 2003;73(9):712-6. doi: 10.1046/j.1445-2197.2003.02748

421 7) McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a  
422 systematic review and meta-analysis of diagnostic test accuracy studies:the

- 423 PRISMA-DTA Statement. *JAMA* 2018;319:388–396. doi:  
424 10.1001/jama.2017.19163
- 425 8) Cata JP, Hagan KB, Bhavsar SD, et al. The use of isoflurane and desflurane as  
426 inhalational agents for glioblastoma surgery. A survival analysis. *J Clin Neurosci*.  
427 2017;35:82-7. doi: 10.1016/j.jocn.2016.10.006
- 428 9) Boisson-Bertrand D, Laxenaire M, Mertes P. Recovery after Prolonged  
429 Anaesthesia for Acoustic Neuroma Surgery: Desflurane versus Isoflurane.  
430 *Anaesthesia and Intensive Care*. 2006;34(3):338-342. doi:  
431 10.1177/0310057X0603400302
- 432 10) Dube SK, Pandia MP, Chaturvedi A, et al. Comparison of intraoperative brain  
433 condition, hemodynamics and postoperative recovery between desflurane and  
434 sevoflurane in patients undergoing supratentorial craniotomy. *Saudi J Anaesth*.  
435 2015;9(2):167-73. doi: 10.4103/1658-354X.152866
- 436 11) Magni G, Rosa IL, Melillo G, et al. A comparison between sevoflurane and  
437 desflurane anesthesia in patients undergoing craniotomy for supratentorial  
438 intracranial surgery. *Anesth Analg*. 2009;109(2):567-71. doi:  
439 10.1213/ane.0b013e3181ac1265
- 440 12) Kaye AD, Kaye A, Kucera IJ, et al. The comparative effects of desflurane and  
441 isoflurane on lumbar cerebrospinal fluid pressure in patients undergoing  
442 craniotomy for supratentorial tumors. *Anesth Analg*. 2004;98(4):1127-32. doi:  
443 10.1213/01.ANE.0000105862.78906.3D
- 444 13) Bastola P, Bhagat H, Wig J. Comparative evaluation of propofol, sevoflurane and  
445 desflurane for neuroanaesthesia: A prospective randomised study in patients

- 446           undergoing elective supratentorial craniotomy. *Indian J Anaesth.* 2015;59(5):287-  
447           94. doi: 10.4103/0019-5049.156868.
- 448       14) Bilotta F, Doronzio A, Cuzzone V, et al. Early postoperative cognitive recovery  
449           and gas exchange patterns after balanced anesthesia with sevoflurane or  
450           desflurane in overweight and obese patients undergoing craniotomy: a prospective  
451           randomized trial. *J Neurosurg Anesthesiol.* 2009;21(3):207-13. doi:  
452           10.1097/ANA.0b013e3181a19c52
- 453       15) Yildiz K, Bicer C, Aksu R, et al. A comparison of 1 minimum alveolar  
454           concentration desflurane and 1 minimum alveolar concentration isoflurane  
455           anesthesia in patients undergoing craniotomy for supratentorial lesions. *Curr Ther*  
456           *Res Clin Exp.* 2011;72(2):49-59. doi: 10.1016/j.curtheres.2011.03.001
- 457       16) Paul AP, Vedantam A, Korula G, Et al. A comparison of the recovery profiles of  
458           desflurane and isoflurane anesthesia in patients undergoing elective supratentorial  
459           craniotomy: A randomized controlled trial. *Neurol India.* 2017;65(5):1053-8. doi:  
460           10.4103/neuroindia.NI\_1136\_15
- 461       17) Gökçek E, Kaydu A, Akdemir MS, et al. Early postoperative recovery after  
462           intracranial surgical procedures. Comparison of the effects of sevoflurane and  
463           desflurane. *Acta Cir Bras.* 2016;31(9):638-44. doi: 10.1590/S0102-  
464           865020160090000010
- 465       18) Haldar R, Kannaujia AK, Verma R, et al. Randomized Trial to Compare Plasma  
466           Glucose Trends in Patients Undergoing Surgery for Supratentorial Gliomas under  
467           Maintenance of Sevoflurane, Desflurane, and Propofol. *Asian J Neurosurg.*  
468           2020;15(3):579-86. doi: 10.4103/ajns.AJNS\_235\_20

- 469 19) Badenes R, Nato C, Peña J, et al. Inhaled anesthesia in neurosurgery: Still a role?.
- 470 *Best Practice & Research Clinical Anaesthesiology*. 2021;35(2):231-240. doi:
- 471 10.1016/j.bpa.2020.10.004
- 472 20) Chen G, Zhou Y, Shi Q, et al. Comparison of early recovery and cognitive
- 473 function after desflurane and sevoflurane anaesthesia in elderly patients: A meta-
- 474 analysis of randomized controlled trials. *J Int Med Res*. 2015;43(5):619-28. doi:
- 475 10.1177/0300060515591064
- 476 21) Singh PM, Borle A, McGavin J, et al. Comparison of the Recovery Profile
- 477 between Desflurane and Sevoflurane in Patients Undergoing Bariatric Surgery-a
- 478 Meta-Analysis of Randomized Controlled Trials. *Obes Surg*. 2017;27(11):3031-
- 479 9. doi: 10.1007/s11695-017-2929-6
- 480 22) Gupta A, Stierer T, Zuckerman R, et al. Comparison of recovery profile after
- 481 ambulatory anesthesia with propofol, isoflurane, sevoflurane and desflurane: a
- 482 systematic review. *Anesth Analg*. 2004;98(3):632-41. doi:
- 483 10.1213/01.ane.0000103187.70627.57
- 484 23) Chen W, Chiang M, Hung K, et al. Adverse respiratory events with sevoflurane
- 485 compared with desflurane in ambulatory surgery. *European Journal of*
- 486 *Anaesthesiology*. 2020;37(12):1093-1104. doi: 10.1097/EJA.0000000000001375
- 487 24) Ghoneim AA, Azer MS, Ghobrial HZ, et al. Awakening properties of isoflurane,
- 488 sevoflurane, and desflurane in pediatric patients after craniotomy for
- 489 supratentorial tumours. *J Neurosurg Anesthesiol*. 2015;27(1):1-6. doi:
- 490 10.1097/ANA.0000000000000058
- 491
- 492

493 Figure legends:

494 Fig 1: PRISMA flow diagram

495 Fig 2: Risk of bias assessment: Rob 2 scores

496

497

498

499

500

501 Supplemental digital Content 1: SDC table.docx, The PICOS model

502 Supplemental digital Content 2: MINORs scores.docx, MINORs scores

503

504

505